NCT06041438已完成1 期
Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1584862 in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Design Study)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Maximum measured concentration of the analyte in plasma (Cmax)
研究概览
简要总结
The main objective of this trial is to investigate the effect on the exposure of BI 1584862 in plasma when given as single dose together with multiple doses of itraconazole (Test, T) as compared to BI 1584862 when given alone as oral single dose (Reference, R).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
- •Age of 18 to 50 years (inclusive)
- •Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
- •Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
排除标准
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- •History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply
结局指标
主要结局
Maximum measured concentration of the analyte in plasma (Cmax)
时间窗: Up to 3 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
时间窗: Up to 3 days
次要结局
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)(Up to 3 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the BloodHealthyNCT05965583Boehringer Ingelheim14
已完成
1 期
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 474121 in the BloodHealthyNCT04716894Boehringer Ingelheim14
已完成
1 期
A Study to Assess the Effect of Itraconazole Capsules on the Pharmacokinetics of ZX-7101A Tablets in Healthy Adult Subjects in ChinaPharmacokineticsNCT05949385Nanjing Zenshine Pharmaceuticals16
已完成
1 期
Effect of Itraconazole on the Pharmacokinetics of ApatinibNeoplasmsNCT02836171Jiangsu HengRui Medicine Co., Ltd.20
已完成
1 期
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.HealthyNAFLDNCT04845646Gannex Pharma Co., Ltd.24